Core Insights - H.C. Wainwright upgraded Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to a "Buy" rating and increased its price target from $568 to $620, reflecting confidence in the company's future performance [1][5] - The current stock price of MDGL is $559.40, showing a 3.19% increase, indicating strong investor interest and market activity [3][5] - Madrigal's market capitalization is approximately $12.41 billion, highlighting its significant presence in the biopharmaceutical sector [4] Company Developments - Madrigal Pharmaceuticals granted equity awards to new non-executive employees as part of its 2025 Inducement Plan, which includes 2,125 restricted stock units designed to attract talent and ensure employee retention [2][5] - The stock has fluctuated between $535 and $563.50 today, with a yearly high of $577.90 and a low of $265, reflecting its volatility and growth potential [3]

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. Live webcasts and recordings of these presentations will be availa ...

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City. Investo ...

Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the dev ...

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK). Global plaintiffs’ rights firm Hagens Berman is actively investigating the alleged claims. The firm urges investors in ...

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Society for Immu ...

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Remeasuring Biotech Pipelines: The Valuation Signal Investors ...

– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for the treatment ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - AnaptysBio has filed a Verified Complaint against Tesaro and GSK, alleging material breaches of their Collaboration Agreement and seeking legal remedies [1][2]. Group 1: Legal Disputes - Anaptys claims that Tesaro breached the Collaboration Agreement by participating in clinical trials with competing PD-1 antagonists and failing to use reasonable efforts to maximize commercial returns for Jemperli [2]. - Tesaro has initiated its own lawsuit against Anaptys, alleging that Anaptys improperly claimed breaches of the Collaboration Agreement [4]. - The parties are seeking an expedited trial schedule in Delaware Chancery Court, with a trial expected in July 2026 [5]. Group 2: Financial Implications - Anaptys is entitled to royalties from Jemperli sales, structured as 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [7]. - A one-time $75 million commercial sales milestone is anticipated once Jemperli achieves $1 billion in worldwide net sales [7]. - Anaptys estimates that Sagard will accrue $250 million in royalties and sales milestones through the end of 2025, with full paydown expected between Q2 2027 and Q2 2028 [9]. Group 3: Background of the Collaboration - The Collaboration Agreement was established in March 2014, allowing Tesaro to develop Jemperli for various solid tumor indications [6]. - Anaptys previously filed a complaint against GSK in 2020 regarding breaches related to GSK's clinical trial of Zejula, which resulted in a settlement that included cash payments and increased royalties on Jemperli [3]. Group 4: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes multiple therapeutic candidates [10]. - The company plans to separate its biopharma operations from its royalty assets by the end of 2026 to better align with investor interests [11].